Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenobamate first add-on versus subsequent add-on in adult drug-resistant focal epilepsy
ChiCTR2600133058Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cenobamate in Focal Onset Epilepsy (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: 6-Month ≥50% Responder Rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cenobamate
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on ChiCTR2600133058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133058.